{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T07:37:40Z","timestamp":1792913860615,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01937-1","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:32:57Z","timestamp":1791426777000},"page":"5777-5791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials"],"prefix":"10.1007","volume":"16","author":[{"given":"Andrew E.","family":"Pink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakiya P.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"1937_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.","journal-title":"Nat Rev Dis Primers"},{"key":"1937_CR2","doi-asserted-by":"publisher","first-page":"adv00294","DOI":"10.2340\/00015555-3653","volume":"100","author":"K Ezzedine","year":"2020","unstructured":"Ezzedine K, Shourick J, Merhand S, Sampogna F, Taieb C. Impact of atopic dermatitis in adolescents and their parents: a French study. Acta Derm Venereol. 2020;100:adv00294.","journal-title":"Acta Derm Venereol"},{"key":"1937_CR3","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1111\/ijd.14763","volume":"59","author":"G Birdi","year":"2020","unstructured":"Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta-analysis. Int J Dermatol. 2020;59:e75\u201391.","journal-title":"Int J Dermatol"},{"key":"1937_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.anai.2020.07.005","volume":"125","author":"MR Hong","year":"2020","unstructured":"Hong MR, Lei D, Yousaf M, et al. A real-world study of the longitudinal course of adult atopic dermatitis severity in clinical practice. Ann Allergy Asthma Immunol. 2020;125:686-92.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1937_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/bjd\/ljae080","volume":"191","author":"R Ramessur","year":"2024","unstructured":"Ramessur R, Dand N, Langan SM, et al. Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research: an interdisciplinary perspective. Br J Dermatol. 2024;191:14\u201323.","journal-title":"Br J Dermatol"},{"key":"1937_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","volume":"154","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154:903\u201312.","journal-title":"JAMA Dermatol"},{"key":"1937_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1937_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.anai.2018.07.042","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018;121:604-12.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1937_CR9","doi-asserted-by":"publisher","first-page":"644760","DOI":"10.3389\/fmed.2021.644760","volume":"8","author":"FJ Legat","year":"2021","unstructured":"Legat FJ. Itch in atopic dermatitis\u2014what is new? Front Med (Lausanne). 2021;8:644760.","journal-title":"Front Med (Lausanne)"},{"key":"1937_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/jvc2.100","volume":"2","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Simpson EL, Silverberg JI, et al. Efficacy of dupilumab in moderate and severe atopic dermatitis. JEADV Clin Pract. 2023;2:247\u201360.","journal-title":"JEADV Clin Pract"},{"key":"1937_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaip.2018.10.021","volume":"7","author":"KK Brar","year":"2019","unstructured":"Brar KK, Nicol NH, Boguniewicz M. Strategies for successful management of severe atopic dermatitis. J Allergy Clin Immunol Pract. 2019;7:1\u201316.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1937_CR12","doi-asserted-by":"publisher","first-page":"10s","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22:10s-s16.","journal-title":"J Cutan Med Surg"},{"key":"1937_CR13","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1089\/derm.2022.0087","volume":"35","author":"S Narla","year":"2024","unstructured":"Narla S, Silverberg JI. Which clinical measurement tools for atopic dermatitis severity make the most sense in clinical practice? Dermatitis. 2024;35:S13-s23.","journal-title":"Dermatitis"},{"key":"1937_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.clindermatol.2018.05.012","volume":"36","author":"R Chopra","year":"2018","unstructured":"Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol. 2018;36:606\u201315.","journal-title":"Clin Dermatol"},{"key":"1937_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1937_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","volume":"132","author":"DK Chu","year":"2023","unstructured":"Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on practice parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2023;132:274\u2013312.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1937_CR17","doi-asserted-by":"publisher","first-page":"745.e1","DOI":"10.1016\/j.jaad.2025.05.1386","volume":"93","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93:745.e1\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"1937_CR18","unstructured":"US Food and Drug Administration (FDA). Cibinqo (abrocitinib). Prescribing Information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213871s004lbl.pdf. Accessed 15 May 2025."},{"key":"1937_CR19","unstructured":"European Medicines Agency (EMA). Cibinqo (abrocitinib). Summary of product characteristics. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf. Accessed 15 May 2025."},{"key":"1937_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255\u201366.","journal-title":"Lancet"},{"key":"1937_CR21","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:863\u201373.","journal-title":"JAMA Dermatol"},{"key":"1937_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022;87:351\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1937_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101\u201312.","journal-title":"N Engl J Med"},{"key":"1937_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157:1165\u201373.","journal-title":"JAMA Dermatol"},{"key":"1937_CR25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155:1371\u20139.","journal-title":"JAMA Dermatol"},{"key":"1937_CR26","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/all.15969","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Facheris P, Gomez-Arias PJ, et al. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis. Allergy. 2024;79:1258\u201370.","journal-title":"Allergy"},{"key":"1937_CR27","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37:2056\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1937_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400:273\u201382.","journal-title":"Lancet"},{"key":"1937_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","volume":"74","author":"M Futamura","year":"2016","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74:288\u201394.","journal-title":"J Am Acad Dermatol"},{"key":"1937_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11\u201318.","journal-title":"Exp Dermatol"},{"key":"1937_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181:761\u20139.","journal-title":"Br J Dermatol"},{"key":"1937_CR32","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.jid.2019.03.1152","volume":"139","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Validation and interpretation of short form 12 and comparison with dermatology life quality index in atopic dermatitis in adults. J Invest Dermatol. 2019;139:2090-7.e3.","journal-title":"J Invest Dermatol"},{"key":"1937_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The children\u2019s dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942\u20139.","journal-title":"Br J Dermatol"},{"key":"1937_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s13555-019-00333-2","volume":"9","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, de Bruin-Weller M, Eckert L, et al. Responder threshold for patient-oriented eczema measure (POEM) and children\u2019s dermatology life quality index (CDLQI) in adolescents with atopic dermatitis. Dermatol Ther. 2019;9:799\u2013805.","journal-title":"Dermatol Ther"},{"key":"1937_CR35","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/bjd.16317","volume":"178","author":"J Thomson","year":"2018","unstructured":"Thomson J, Wernham AGH, Williams HC. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Br J Dermatol. 2018;178:897\u2013902.","journal-title":"Br J Dermatol"},{"key":"1937_CR36","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/bjd.17242","volume":"179","author":"J Thomson","year":"2018","unstructured":"Thomson J, Wernham AGH, Williams HC. Response to critical appraisal of LIBERTY AD CHRONOS: reply from authors. Br J Dermatol. 2018;179:1424.","journal-title":"Br J Dermatol"},{"key":"1937_CR37","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/jdv.70439","volume":"40","author":"MJ Gooderham","year":"2026","unstructured":"Gooderham MJ, Silverberg JI, De Bruin-Weller M, et al. Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2 years. J Eur Acad Dermatol Venereol. 2026;40:1372\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1937_CR38","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38:2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1937_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.063","author":"SG Brooks","year":"2024","unstructured":"Brooks SG, Lopez LM, Mashoudy KD, Yosipovitch G, Czarnowicki T. 689\u2014Unmet needs of managing atopic dermatitis: where do we stand in modifying vs. suppressing disease? Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.063.","journal-title":"Br J Dermatol"},{"key":"1937_CR40","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2024.09.022","volume":"134","author":"T Bieber","year":"2025","unstructured":"Bieber T. The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol. 2025;134:144\u201350.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1937_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1937_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/jdv.19500","volume":"38","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38:340\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1937_CR43","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s13555-024-01146-8","volume":"14","author":"S Gkalpakiotis","year":"2024","unstructured":"Gkalpakiotis S, Kannenberg S, Kingo K, et al. Real-world clinical, psychosocial, and economic burden of atopic dermatitis: results from the ESSENTIAL AD multicountry study. Dermatol Ther. 2024;14:1173\u201387.","journal-title":"Dermatol Ther"},{"key":"1937_CR44","unstructured":"Silverberg JI, Lio PA, Boguniewicz M, et al. Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD) in bio-experienced and bio-na\u00efve patients: results from longitudinal analyses of the CorEvitas AD registry. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) 2025 Annual Meeting, 6\u20137 June 2025, Nashville."},{"key":"1937_CR45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jvc2.203","volume":"2","author":"MJ Gooderham","year":"2023","unstructured":"Gooderham MJ, Ardern-Jones MR, Guttman-Yassky E, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: a post hoc analysis of the JADE clinical trials. JEADV Clin Pract. 2023;2:753\u201363.","journal-title":"JEADV Clin Pract"},{"key":"1937_CR46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s13555-026-01679-0","volume":"16","author":"HE Gwag","year":"2026","unstructured":"Gwag HE, Park M, Park SY, et al. Real-world effectiveness and safety of abrocitinib in patients with atopic dermatitis: a 16-week single-center retrospective cohort study compared with upadacitinib and baricitinib. Dermatol Ther. 2026;16:1813\u201330.","journal-title":"Dermatol Ther"},{"key":"1937_CR47","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1007\/s13555-026-01833-8","volume":"16","author":"S Weidinger","year":"2026","unstructured":"Weidinger S, Reich K, Issa N, et al. Abrocitinib achieves early and complete\/near-complete skin clearance plus itch-free state in atopic dermatitis: phase 3 pooled post hoc analysis. Dermatol Ther. 2026;16:4217\u201325.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01937-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01937-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T07:01:42Z","timestamp":1792911702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01937-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1937"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01937-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andrew E. Pink has acted as investigator, advisor, speaker, and received educational and\/or research support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Celgene, Galderma, J&J, Leo, Lilly, Novartis, Pfizer, Sanofi, and UCB. Zakiya P. Rice has been an investigator, speaker, consultant, and\/or advisor for AbbVie, Anacor Pharmaceuticals, Brickell Biotech, Cassiopeia, Celgene Pharmaceuticals, Galderma, Incyte, Merck & Co., Organon, Pfizer Inc., and Regeneron\/Sanofi Genzyme; holds equity, stock or options in Pantones LLC; and is a board director or officer of the\u00a0American Academy of Dermatology and Georgia Society of Dermatology and Dermatological Surgery. Melinda J. Gooderham has been an investigator, speaker, and\/or advisor for AbbVie, Acelyrin, Alumis, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, LEO Pharma, L\u2019Oreal, MedImmune, Meiji, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx, and Vyne. Fang Wang received grants from Pfizer and has served as an advisor or speaker for Pfizer Inc., AbbVie, LEO Pharma, and Sanofi Genzyme. Andreas Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by AbbVie, Aileens, Almirall, Amgen, Apogee, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, LEO Pharma, L\u2019Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis, and UCB. Pinaki Biswas, Gary Chan, Justine Alderfer, and Melissa Watkins are employees and shareholders of Pfizer Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent. The trials were conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines. All local regulatory requirements were followed. Study investigators were responsible for prospective approval of the study protocol, protocol amendments, informed consent\/assent documents, and other relevant documents by the institutional review board or ethics committee at each institution participating in each study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}